Welcome to
National Cancer Centre Singapore

NCC Profile


About Us

Board of Director


To be a global leading cancer centre.


  • We deliver multidisciplinary care to every patient.
  • We conduct cutting edge clinical and translational research.
  • We are the institutional home for the best cancer professionals and researchers through learning and innovation.
  • We lead and promote anti-cancer advocacy.

Our Core Values : 


  • Treat everyone with kindness, respect and dignity.
  • Sensitive to patient's and their families' needs and their right to privacy.


  • Adhere to the highest standard of professional conduct and ethical behaviour.


  • Deal with diversity with an open-mind and value the contributions of all who are working together to achieve our common goals.

Common Purpose :

We offer our patients hope by having the best people, providing the best care, and doing the best research.


Years Event
1992 The Singapore Government reviewed National Health Policies and recommended the establishment of a national cancer centre in Singapore.  
1993 NCCS commenced as a specialised Strategic Business Unit within the Singapore General Hospital (SGH).
1996 New premises for NCCS was launched by Minister for Health, BG (NS) George Yeo at a groundbreaking ceremony.
1997 NCCS obtained its status of National Specialist Centre with its own Board of Management.
1999 NCCS officially opened and commenced operations with two clinical divisions - Medical Oncology and Radiation Oncology, and three research divisions - Division of Cellular and Molecular, Division of Medical Sciences, and Division of Clinical Trials & Epidemiological Sciences. Divisions of Surgical Oncology, Palliative Medicine and Oncologic Imaging were also established within the year.

NCCS became part of Singapore Health Services (SingHealth), one of two Singapore public Academic Medical Centres.
NCCS’ Mammography Suite was established within the year.

2001 Department of Psychosocial Oncology was established.

NCCS established the Cryopreservation Laboratory.
NCCS Division of Radiation Oncology introduced Singapore’s first Intensity Modulated Radiotherapy (IMRT) treatment to improve tumour coverage and decrease side effects of treatment.

2004 NCCS pioneered a new technique, Photodynamic Diagnosis and Treatment (PDT) that uses fluorescence diagnosis and drug-induced light therapy to diagnose and treat cancer.

NCCS signed a landmark agreement with eight Asian National Cancer Centres to collectively embark on cancer prevention advocacy, cancer research, training, as well as collaboration, with the World Health Organisation (WHO) and International Agency for Research on Cancer (IARC).
NCCS became the secretariat for the Asian National Cancer Centres Syndicate.

NCCS partnered the Children Cancer Foundation and KKH Women and Children’s Hospital for research on rhabdomyosarcoma, a fast growing malignant tumour that affects children.

2006 NCCS acquired a 64-slice Multi-Detector Computed Tomography (MDCT) to enable early detection and treatment of cancer.

Signed an MOU with Rajiv Gandhi Centre for Biotechnology and Regional Cancer Centre in Thiruvananthapuram (India) to conduct biomedical research and to study head and neck cancers.

NCCS led Singapore’s first bench-to-bedside Dendritic Cell Vaccine trial that produces encouraging results for advanced colon cancer patients.

NCCS established the Health Professionals and Undergraduates (HPU) Education Unit to provide training opportunities for medical students to learn from veteran medical staff and clinicians.


NCCS established Geriatric Oncology Programme.

Signed an international collaboration agreement formalising an alliance to customise Asian patients’ cancer drug response, with the Van Andel Research Institute (VARI) based in Michigan, USA.

NCCS established the Humphrey Oei Institute of Cancer Research (HOICR). This institute comprises the three founding research divisions: Cellular and Molecular Research, Medical Sciences and Clinical Trials and Epidemiological Sciences, which were set up in 1999.


NCCS introduced Image Guided Radiotherapy (IGRT), a new technique that enhances cancer control with lesser side effects.

NCCS partnered Four Seasons Hotel Singapore and The Regent Singapore for the inaugural launch of the annual Run For Hope to raise funds for cancer research.

Minister for Health Mr Khaw Boon Wan opened the Lien Centre for Palliative Care.


NCCS initiated the Joint Commission International (JCI) accreditation process in January.

NCCS launched the BNP Paribas-NCCS Regional Fellowship Programme. The first programme was conferred to a physician from Vietnam.

NCCS Department of Radiation Oncology introduced Tomotherapy, a type of radiation therapy that delivers more precise radiation treatment to cancerous sites.


NCCS embarked on its Service Quality Excellence Programme.

NCCS Division of Medical Oncology introduced a phase 3 Clinical Trial on colorectal cancer that will involve 2,660 subjects to evaluate the efficacy of aspirin in reducing the risk of recurrence of colorectal cancer post-surgery and chemotherapy.

NCCS received accreditation from the Joint Commission International (JCI). It is the only national cancer centre in the region to be accorded the highest accolades for healthcare standards on patient safety and clinical governance.

NCCS supported the proposal to deny the purchase of tobacco products for citizens born in or after the year 2000. The proposal was presented at the SingHealth-Duke-NUS Scientific Congress to various stakeholders.


NCCS opened Centre for Peritoneal and Pelvic Cancers.

NCCS partnered Wellcome Trust Sanger Institute (UK) and Van Andel Research Institute (USA) leading to the discovery of a new gene that is mutated in one out of three cancer patients with renal cancers.

NCCS embarked on genome sequencing project to study possible disease pathways.

NCCS Division of Medical Oncology introduced a comprehensive geriatric assessment to elderly patients with colorectal, lung and genitourinary cancers to assess their suitability for treatment.

NCCS Division of Surgical Oncology introduces the Breast Cancer Survivorship Programme, which enables survivors to receive comprehensive disease surveillance assistance from Advanced Practitioner Nurses.


NCCS partnered BNP Paribas to launch the first NCCS Surgical Oncology Conference.

NCCS announced its plans to offer Proton Therapy to patients in 2020/2021.

NCCS introduced Intraoperative Radiotherapy (IORT) for breast cancer patients.

2013 NCCS signed Master Research Collaboration Agreement with Singapore General Hospital and Australia’s Sirtex Medical Pte Ltd to explore the potential of a new technology called Carbon Cage Nanoparticles.

NCCS launched NCCS Oncology Clinic @ CGH (Changi General Hospital).

NCCS set up the Integrated Translational Oncology Network together with Bayer Heathcare, Cancer Science Institute of Singapore, Duke-NUS Medical School, National University Cancer Institute, Singapore, Singapore General Hospital, A*STAR's Singapore Bioimaging Consortium.

JCI granted NCCS re-accreditation.


NCCS collaborated with Clearbridge BioMedics, together with the Pathology Department of the Singapore General Hospital, to set up region’s first Circulating Tumour Cell Centre of Research Excellence (CTC CoRE).

NCCS signed the Goyang Declaration in Seoul to push for a Tobacco-Free Generation (TFG) in Asia.

NCCS received $50 million donation from the Goh Foundation for setting up of new Proton Beam Treatment Centre and for proton related cancer treatment research.

2015 NCCS collaborated with ASLAN Pharmaceuticals to research and develop therapies for Asia-Prevalent Tumour Types.

NCCS won Service Excellence Medallion Award, making it the first healthcare institution in Singapore to receive this award.

2016 NCCS awarded contract for Proton Beam Therapy System to Hitachi Asia Ltd.

NCCS groundbreaking ceremony for the New NCCS Building. The new comprehensive proton therapy facility located within the new building is named the Goh Cheng Liang Proton Therapy Centre.

Founding Director, Prof Soo Khee Chee retires and relinquished the appointment as Director of NCCS on 26 November 2017 and Prof William Hwang was appointed as Medical Director of NCCS on the same date. Prof Hwang has a strong track record of multiple leadership portfolios having previously served as Director, SingHealth Transplant; Head, SingHealth Duke-NUS Blood Cancer Centre; Head, Department of Haematology, Singapore General Hospital; Medical Director, Singapore Cord Blood Bank and President of the World Marrow Donor Association.


Launched Fundraising Capital Campaign to raise $150m for Patient Care, Education and Research.



Cancer Genetics Service Click for detail
Psychosocial Oncology Click for detail
Patient Care Specialities and Services Click for detail
Cellular and Molecular Research Click for detail
Medical Sciences Click for detail






Name:National Cancer Center Singapore
Date of establishment:1999
Organization Type : Healthcare
Total number of staff:1118 staff
Name:Division of Cellular and Molecular
Date of establishment:NA
Organization Type : Departments (1)
Number of beds:NA
Total number of staff: Total of 43 (2 BI Specialists, 2 Senior RF, 10 RF, 2 Senior RA, 4 RA, 2 Senior RO, 18 RO, 3 RT)
Name:Division of Medical Sciences
Organization Type : Departments (2)
Number of beds:NA
Total number of staff:Total of 68 (1 BI Specialist, 2 Senior Scientists, 2 Senior RF, 15 RF, 3 Senior RA, 6 RA, 3 Senior RO, 30 RO, 2 Senior RT, 4 RT)
Name:Division of Clinical Trials & Epidemiological Sciences
Date of establishment:NA
Organization Type : Departments (3)
Number of beds:NA
Total number of staff:NA
Name:Division of Community Outreach & Philanthropy
Date of establishment:NA
Organization Type : Departments (4)
Number of beds:NA
Total number of staff:NA
Name:Division of Cancer Education
Date of establishment:NA
Organization Type : Departments (5)
Number of beds:NA
Total number of staff:NA
Name:Division of Cellular and Molecular
  • Bek Chai Heah Laboratory of Cancer Genomics
  • Laboratory of Molecular Carcinogenesis
  • Laboratory of Molecular Endocrinology
  • Laboratory of Liver Cancer Functional Genomics
  • Laboratory of Cancer Signalling Lymphoma Genomic
  • Translational Research Laboratory
  • Laboratory of Molecular Oncology
  • Laboratory of Clinical Pharmacology
Name:Division of Medical Sciences
  • Medical Sciences
  • Laboratory of Cancer Epigenome
  • Cancer Therapeutics Research Laboratory
  • Laboratory of Cell Therapy and Cancer Vaccine
  • Tan Chin Tuan Lab of Optical Imaging and Photodynamic & Proton Therapy
  • Laboratory of Translational Research in Gastrointestinal Cancer
  • Laboratory of Genomic Medicine
  • Programme in Translational and Clinical Liver Research
  • Translational Cancer Biology Laboratory
  • Laboratory of Applied Human Genetics
  • Laboratory of Haematopoietic Stem Cells, Blood Cancers and Cellular Therapy
Name:Division of Clinical Trials & Epidemiological Sciences
  • Clinical Trials Office
  • Biostatistics & Epidemiology Unit
  • Epidemiology Unit
Name:Division of Community Outreach & Philanthropy
  • Governance & Administration
  • Community Partnership
  • Corporate Communications
Name:Corporate Services
  • Ambulatory & Clinical Support Services
  • Strategic Development
  • Operations
  • Finance
  • Human Resource
  • Materials Management & Development
  • Clinic Operations
  • Information Systems (Outsourced)
  • Division of Medical Oncology
  • Division of Radiation Oncology
  • Division of Surgical Oncology
  • Division of Oncologic Imaging
  • Division of Supportive & Palliative Care
  • Nursing
  • Medical Affairs
  • Cancer Informatics
Name:Division of Cancer Education
  • Postgraduate Education Unit
  • Nursing & Allied Health Education Unit
  • Undergraduate Education Unit
  • Faculty Development & Support Education Unit
  • Ethics & Professionalism Education Unit

Key Activities

  • Multidisciplinary and team-based care
  • Aims to be the leading charity that helps make a cancer free future through research, education and patient support
  • The Cancer Education and Information Service (CEIS) of NCCS promotes cancer awareness, prevention and early detection through regular public forums, campaigns, workshops and publications on cancer information.

Key Research

  • Asian Cancer Genomics
  • HSA-registered Clinical Trials
  • Cancer Therapeutics
  • Proton Beam Therapy
  • Cancer Genetics
  • Supportive & Palliative Care Research
  • Translational Imaging

Cancer Profile

Total Population 5,303,000
Income Group High
Total Deaths 23,000
Life Expectancy at birth Total 83
Male 80
Female 85
Cancer Mortality Profile
Age-Standardized Cancer Mortality Trends
Cancer Incidence
Adult Risk Factors Current tobacco smoking (2011 Data) Males NA
Females NA
Total NA
Total alcohol per capita consumption, in litres of pure alcohol (2010 Data) Males 2.8
Females 1.2
Total 2
Physical inactivity (2010 Data) Males 31.6%
Females 35.7%
Total 33.7%
Obesity (2014 Data) Males 6.1%
Females 7.4%
Totals 6.8%
Household solid fuel use (2012 Data) Males NA
Females NA
Total 0%
Cancer Plans, Monitoring, and Surveillance Has an operational cancer policy/strategy/action plan Yes
Has a cancer registry    
Scope Population-based
Coverage National
Last Year of Data 2011
Cancer Primary Prevention Policies Tobacco Control Has an operational policy, strategy or action plan to reduce the burden of tobacco use Yes
Smoke-free legislation Data not categorized
Tobacco dependence treatment National quit line, and both NRT and some cessation services cost- covered*
Warning labels Large warning with all appropriate characteristics*
Bans on advertising, promotion and sponsorship Ban on national television, radio and print media as well as on some but not all other forms of direct and/or indirect advertising
Tobacco taxes 51-75% of retail price is tax
Overweight and obesity prevention and control Has an operational policy, strategy or action plan for reducing overweight/obesity Yes
Physical inactivity prevention and control Has an operational policy, strategy or action plan to reduce physical inactivity and/or promote physical activity Yes
Harmful use of alcohol prevention and control Has an operational policy, strategy or action plan to reduce the harmful use of alcohol No
National Immunization Human Papillomavirus vaccination schedule 9-26 yeasr (3x)
Hepatitis B vaccination schedule Birth, +1 month, +5-6 months
Hepatitis B vaccination coverage, infants 97%
Cancer Screening and Early Detection Cervical Cancer Cervical cytology (PAP) Generally available at the public primary health care level
Acetic Acid Vizualization (VIA) Generally available at the public primary health care level
Breast Cancer Breast palpation / clinical breast exam (CBE) Generally available at the public primary health care level
Mammogram Generally available at the public primary health care level
Colorectal Cancer Faecal occult blood test or faecal immunological test Generally available at the public primary health care level
Bowel cancer screening by exam or colonoscopy Generally available at the public primary health care level
Cancer Treatment and Palliative Care Radiotherapy Generally available in the public health system
Total high energy teletherapy units / million inhabitants 4
Number of radiotherapy centres 4
Number of radiation oncologists 14
Chemotherapy (medicines not specified) Generally available in the public health system
Oral morphine (formulation not specified) Generally available in the public health system
Non-methadone morphine equivalent consumption per cancer death (mg) 6045.4
Community/home care for people with advanced stage cancer and other NCDs Generally available
REMARKS * Indicates highest possible level of achievement
SOURCE Extracted from: WHO Cancer Country Profiles 2014 (https://www.who.int/cancer/country-profiles/sgp_en.pdf?ua=1) as of 2019/05/30

Stay connect with us


Please complete the form below to send us an E-Mail. For security and anti-spam purposes, we do not post our E-Mail addresses on our website.